[en] Angioplasty, Transluminal, Percutaneous Coronary/adverse effects ; Anti-Inflammatory Agents/therapeutic use ; Antioxidants/therapeutic use ; Belgium/epidemiology ; Cardiovascular Agents/therapeutic use ; Coronary Restenosis/epidemiology/prevention & control ; Coronary Thrombosis/therapy ; Diabetes Complications/prevention & control ; Diabetes Mellitus, Type 2/complications ; Drug Therapy, Combination ; Evidence-Based Medicine ; Fatty Acids, Omega-3/therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hypoglycemic Agents/therapeutic use ; Immunologic Factors/therapeutic use ; Incidence ; Meta-Analysis as Topic ; Platelet Aggregation Inhibitors/therapeutic use ; Randomized Controlled Trials as Topic ; Stents
[en] Various systemic pharmacological approaches have been evaluated to reduce the risk of restenosis after coronary angioplasty, with or without stent, in the general population and in diabetic patients who are at increased risk for such complication. The aim of the present paper is to describe the effects of the main pharmacological classes on the risk of restenosis, the need for new revascularisation procedures and the incidence of major clinical events (MACE: death, myocardial infarction, revascularisation). We will analyse the role of antiplatelet agents, omega-3 fatty acids, statins, anti-inflammatory compounds, immunomodulators, anti-oxidants, glitazones and, finally, classical antidiabetic drugs such as metformin and insulin. Whenever possible, we will focus our attention on the results obtained in the diabetic population.